|
|
 |
|
Viewing report
|
|
|
|
Key Companies: Neuropathic Pain - In-house to in-license as Big Pharma cuts down on early-stage research
Datamonitor, Oct 2011, Pages: 40
Pfizer is endeavouring to defend its market dominance in the neuropathic pain market, offering a diverse and balanced pain portfolio. Meanwhile, the August 2011 Food and Drug Administration (FDA) approval of Nucynta ER (extended release tapentadol) for the treatment of chronic pain points towards Johnson & Johnson and Grünenthal becoming key players in the future neuropathic pain market.
Features and benefits
- Identify the leading companies in the neuropathic pain market and the strengths, weaknesses, opportunities, and threats of their portfolios.
- In-depth discussion of brand lifecycle and portfolio management strategies of key companies in the neuropathic pain market.
- Assess trends in corporate strategies of companies active in the neuropathic pain arena and understand the impact of key recent licensing deals.
- Learn how companies can respond to future opportunities and challenges in the field.
Highlights
-The strong marketing platform offered by large pharmaceutical companies is necessary to penetrate the neuropathic pain sector given the fierce competition from off-label prescribing. As Big Pharma cuts early stage R&D resources and looks to in-license later stage products, smaller companies should look to such partners to bring a product to market.
- Key trends in corporate strategy include indication and geographic expansions for marketed agents in the neuropathic pain field. While improved efficacy remains the major unmet need, the development of treatments with novel mechanisms of action and different modes of delivery are all small but important steps to improve dosing convenience.
- There is mixed interest in the future market due to the high cost and complexities of neuropathic pain research. Pfizer, Grünenthal and Johnson & Johnson all have active pipelines indicating their long-term presence. Meanwhile, a lack of pipeline candidates suggests Eli Lilly and Endo are shifting away from neuropathic pain research altogether.
Your key questions answered
- How successful are the portfolio management strategies most widely used in the neuropathic pain market?
- How can emerging trends in the neuropathic pain market be exploited by leading companies to guide strategic decisions?
- What opportunities remain for Pfizer’s neuropathic pain portfolio before and after Lyrica’s patent expiry?
- What are the implications of Pfizer’s acquisition of King Pharmaceuticals and Icagen?
- How can current and prospective players ensure longevity in the neuropathic pain market?
|
|
|
|
